开发决策支持工具以优化卵母细胞解冻以产生至少三个整倍体囊胚
该回顾性队列研究纳入2012至2024年单一体学术附属生育诊所的417个卵母细胞解冻周期,按解冻卵母细胞数分组,评估获得≥3个整倍体囊胚所需解冻卵母细胞数。结果显示解冻12-16个与>16个在<38岁患者中几率相似,而<12个几率显著降低;≥38岁患者仅3.4%周期获得≥3个整倍体囊胚。
要点
- 年龄<38岁患者解冻12-16个与>16个卵母细胞获得≥3个整倍体囊胚的几率相似。
- 解冻<12个卵母细胞时获得≥3个整倍体囊胚的几率显著低于>16个。
- ≥38岁患者仅3.4%周期获得≥3个整倍体囊胚。
核心结论
- 在<38岁患者中,解冻12-16个卵母细胞与解冻>16个获得≥3个整倍体囊胚的几率相似。
- 玻璃化卵母细胞<12个的患者应解冻所有可用卵母细胞,若有限应考虑额外冷冻周期。
- 玻璃化卵母细胞多的患者可考虑限制解冻至16个,因为解冻全部似乎不提供额外获益以达到一次活产。
研究设计与样本
- 回顾性队列研究,纳入2012至2024年单一体学术附属生育诊所接受卵母细胞冷冻保存并返回解冻的患者。
- 按解冻卵母细胞数分组:A组2-8个(n=109周期)、B组9-11个(n=103)、C组12-16个(n=101)、D组>16个(n=104),共417个解冻周期。
- 排除未使用胚胎植入前非整倍体遗传学检测、一个解冻周期内合并多个冷冻周期或选择新鲜胚胎移植的患者。
主要发现
- D组50.0%患者获得≥3个整倍体囊胚,C组27.7%,B组16.5%,A组5.5%。
- <35岁组中,与D组相比,C组获得≥3个整倍体的比值比相似(aOR 0.47 [0.17-1.34]),A组aOR 0.13 [0.04-0.50],B组aOR 0.10 [0.03-0.41]。
- 35至<38岁组中,与D组相比,C组aOR 0.45 [0.19-1.10],A组aOR 0.06 [0.01-0.28],B组aOR 0.34 [0.13-0.88]。
- ≥38岁组(n=118)仅3.4%周期产生≥3个整倍体囊胚。
关键数值与推荐
- 主要结局为产生≥3个整倍体囊胚所需解冻卵母细胞数。
- 次要结局包括卵母细胞解冻实验室结局。
- 亚组分析按冷冻时年龄分组:<35、35至<38、38至<41、≥41岁。
临床怎么用
- 作者建议<38岁患者解冻12-16个卵母细胞可获得与>16个相似的≥3个整倍体囊胚几率。
- 作者建议玻璃化卵母细胞<12个的患者解冻所有可用卵母细胞或考虑额外冷冻周期。
- 作者建议玻璃化卵母细胞多的患者可考虑限制解冻至16个。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the optimal number of oocytes needed to thaw to yield ≥3 euploid blastocysts. DESIGN: Retrospective cohort study. SUBJECTS: Patients who underwent oocyte cryopreservation and returned for thaw between 2012 and 2024 at a single academic-affiliated fertility clinic. Patients were grouped by number of oocytes thawed (group A: 2-8, group B: 9-11, group C: 12-16, and group D: >16 oocytes). Patients were excluded if they did not use preimplantation genetic testing for aneuploidy, had multiple cryopreservation cycles combined within one thaw cycle, or opted for fresh embryo transfer. EXPOSURE: Number of oocytes thawed. MAIN OUTCOME MEASURES: Primary outcome was the number of oocytes needed to thaw to produce ≥3 euploid blastocysts. Secondary outcomes included oocyte thaw laboratory outcomes. Subgroup analysis was performed by age groups at cryopreservation (<35, 35 to <38, 38 to <41, and ≥41 years). RESULTS: A total of 417 oocyte thaw cycles were included. Overall, 50.0% of patients in group D (>16 oocytes thawed, n = 104 cycles) achieved ≥3 euploid blastocysts, compared with 27.7% in group C (12-16 oocytes, n = 101), 16.5% in group B (9-11 oocytes, n = 103), and 5.5% in group A (2-8 oocytes, n = 109). In age groups <35 and 35 to <38, compared with thaw group D, patients in thaw group C had similar odds of producing ≥3 euploids (<35: adjusted odds ratio [aOR] 0.47 [0.17-1.34]; 35 to <38: aOR 0.45 [0.19-1.10]); however, thaw groups A and B had significantly lower chances compared with group D (<35 years: group A: aOR 0.13 [0.04-0.50], group B: aOR 0.10 [0.03-0.41]; and 35 to <38 years: group A: aOR 0.06 [0.01-0.28], group B: aOR 0.45 (0.34 [0.13-0.88]). Patients in age groups ≥38 years (n = 118) produced ≥3 euploid blastocysts in only 3.4% of cycles. CONCLUSION: In patients <38 years, thawing 12-16 oocytes yields similar chances of producing ≥3 euploid blastocysts compared with thawing >16 oocytes. Patients with <12 vitrified oocytes should thaw all available oocytes or, if limited, should consider additional cryopreservation cycles. Conversely, patients with many vitrified oocytes may consider limiting the thaw to 16 oocytes, because thawing all does not appear to provide additional benefit in achieving one live birth.
引用
- Clarke EA, Hernandez-Nieto C, Bayefsky M, et al. Developing a decision support tool to optimize oocyte thawing for producing at least three euploid blastocysts. Fertil Steril. 2025. PMID: 40518104. doi:10.1016/j.fertnstert.2025.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。